Financial consequences of drug benefit plans [3] (multiple letters)

JAMA

Volumn 289, Issue 4, 2003, Pages 423-424

  Clark, Bartholomew E ^a   Garis, Robert I ^a   Hsu, John ^b   Reed, Mary ^b   Motheral, Brenda ^c   Sheth, Jagat ^c   Joyce, Geoffrey F ^d   Goldman, Dana P ^d  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b DIVISION OF RESEARCH   (United States)

^c Express Scripts Inc ^*  (United States)

^d RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST; COST CONTROL; DRUG COST; DRUG MARKETING; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; LETTER; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; ECONOMICS; FEE; NOTE; UNITED STATES;

GENERIC DRUG;

COST SHARING; DRUG COSTS; DRUGS, GENERIC; HEALTH BENEFIT PLANS, EMPLOYEE; INSURANCE, PHARMACEUTICAL SERVICES; PRESCRIPTION FEES; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 17144471339     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.4.423-a     Document Type: Letter

References (0)